Illumina, Inc. - Company Research Report

Company Overview

Name

• Illumina, Inc.

Mission

• The mission of Illumina is to improve human health by unlocking the power of the genome. The company aims to push the boundaries of genomic possibility to allow researchers and clinicians to accelerate discoveries and applications that heal people and the planet.

Founding

• Founded in 1998.

Key People

• President and CEO: Jacob Thaysen

• Note: There are additional members on the Board of Directors and management team, but specific names and roles are not provided in the available data.

Headquarters

• San Diego, California, USA

Number of Employees

• Over 9,250 employees

Revenue

• Annual revenue of $4.43 billion USD (as of 2023)

Known For

• Illumina is renowned for being a leader in genomics and human health, providing cutting-edge DNA sequencing and array-based life sciences technologies that enable profound research discoveries and personalized health solutions. The company’s products drive advancements in oncology, genetic and infectious diseases, reproductive health, and beyond.

Products

Sequencing Platforms

• MiSeq i100 Series: Offers simplified, fast benchtop sequencing with XLEAP Chemistry and push-button workflows.

• NextSeq 1000 & 2000 Systems: Provides user-friendly, flexible, and reliable sequencing for various applications.

• NovaSeq 6000 System: Delivers large-scale sequencing capabilities for comprehensive genomic profiling.

• TruSight Oncology 500: A large pan-cancer panel enabling comprehensive genomic profiling from FFPE tissues.

Microarray Technology

• Infinium MethylationEPIC Kit: Provides extensive coverage for methylation profiling, ideal for genetic and rare disease research and cancer research.

Key Features of Products

• Advanced sequencing and microarray technologies with high fidelity and throughput.

• Comprehensive bioinformatics solutions for data analysis and insights.

• Flexible and scalable sequencing options ranging from benchtop to production scale.

Recent Developments

New Product Launches

• Oct 9, 2024: Launch of the MiSeq i100 Series, its simplest, fastest benchtop sequencers.

• Launched other products for higher throughput and lower cost, including new chemistries across mid-throughput sequencers.

Innovations

• DRAGEN v4.3: Offers the most comprehensive and accurate genome mapping with industry-leading innovations.

• Launch of the latest chemistry enabling higher quality genome sequencing at lower costs.

Partnerships

• Collaborating with Fluent BioSciences to advance single-cell analysis.

• A strategic partnership with companies like LGC Biosearch Technologies and the Broad Institute for the advancement of genomics technologies and applications.

• Collaboration with Janssen and others to advance molecular residual disease cancer tests.

Corporate Activities

• Completed the divestiture of GRAIL, a company centered on blood-based cancer screening.

• Engaged in a legal battle regarding the acquisition of GRAIL, with significant court rulings in favor and strategic decisions to spin-off.

• Joined by several biopharma giants in the Alliance for Genomic Discovery.

Research and Community Involvement

• Continued investment in genomic research including collaborations with international institutions to expand sequencing capabilities globally.

• Initiatives to improve health outcomes through genomic innovation and accessibility, such as the iHope program providing genomic testing to underserved populations.

Conclusion

Illumina continues to lead in the genomics industry by innovating and delivering cutting-edge sequencing technologies and solutions. Its dedication to improving human health through genome technology is evident in its product advancements, partnerships, and community initiatives. The company remains a pivotal force in driving global genomic research and accessibility.